Therefore, we speculated that NACT should be performed in patients with pretreatment SCC levels ≥3.9 ng/mL, and even if the SCC antigen levels decrease to 3.9 ng/mL after chemotherapy, it could be used as a critical indicator in predicting the sensitivity of lymph node metastases to NACT. Here, SERPINB3 is linked to metastatic malignant neoplasm in the lymph nodes.